Viridian Therapeutics, Inc.

LSE:0K1R Stock Report

Market Cap: US$1.3b

Viridian Therapeutics Valuation

Is 0K1R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0K1R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$281.85
Fair Value
94.1% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 0K1R ($16.71) is trading below our estimate of fair value ($281.85)

Significantly Below Fair Value: 0K1R is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0K1R?

Key metric: As 0K1R barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0K1R. This is calculated by dividing 0K1R's market cap by their current book value.
What is 0K1R's PB Ratio?
PB Ratio2.5x
BookUS$518.61m
Market CapUS$1.29b

Price to Book Ratio vs Peers

How does 0K1R's PB Ratio compare to its peers?

The above table shows the PB ratio for 0K1R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average41.3x
PRTC PureTech Health
1.4x-12.8%UK£340.0m
GNS Genus
2.1x36.6%UK£1.2b
OXB Oxford Biomedica
5.5x96.4%UK£365.6m
FARN Faron Pharmaceuticals Oy
156.1x29.8%UK£177.9m
0K1R Viridian Therapeutics
2.5x39.6%US$1.3b

Price-To-Book vs Peers: 0K1R is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (41.3x).


Price to Book Ratio vs Industry

How does 0K1R's PB Ratio compare vs other companies in the GB Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
LLAI LungLife AI
0.09x101.0%US$697.02k
0HMP Bellerophon Therapeutics
0.1xn/aUS$489.31k
No more companies available in this PB range
0K1R 2.5xIndustry Avg. 2.7xNo. of Companies5PB01.63.24.86.48+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0K1R is good value based on its Price-To-Book Ratio (2.5x) compared to the UK Biotechs industry average (2.8x).


Price to Book Ratio vs Fair Ratio

What is 0K1R's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0K1R PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0K1R's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0K1R forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.79
US$40.44
+140.8%
23.3%US$61.00US$22.00n/a16
Feb ’26US$19.69
US$40.44
+105.4%
23.3%US$61.00US$22.00n/a16
Jan ’26US$19.29
US$40.44
+109.7%
23.3%US$61.00US$22.00n/a16
Dec ’25US$21.55
US$40.63
+88.5%
21.2%US$61.00US$22.00n/a16
Nov ’25US$22.11
US$39.25
+77.5%
21.6%US$56.00US$22.00n/a16
Oct ’25US$23.80
US$39.25
+64.9%
21.6%US$56.00US$22.00n/a16
Sep ’25US$14.86
US$35.19
+136.8%
23.2%US$46.00US$20.00n/a16
Aug ’25US$16.55
US$35.19
+112.6%
23.4%US$46.00US$20.00n/a16
Jul ’25US$13.08
US$35.19
+169.1%
23.4%US$46.00US$20.00n/a16
Jun ’25US$11.90
US$36.50
+206.7%
21.7%US$46.00US$20.00n/a14
May ’25US$13.75
US$39.36
+186.2%
12.0%US$46.00US$30.00n/a14
Apr ’25US$17.53
US$39.36
+124.5%
12.0%US$46.00US$30.00n/a14
Mar ’25US$19.98
US$38.67
+93.5%
13.6%US$46.00US$29.00n/a15
Feb ’25US$20.15
US$39.27
+94.9%
14.9%US$50.00US$29.00US$19.6915
Jan ’25US$21.53
US$39.33
+82.7%
14.8%US$50.00US$29.00US$19.2915
Dec ’24US$16.74
US$39.80
+137.8%
16.1%US$50.00US$29.00US$21.5515
Nov ’24US$12.16
US$41.36
+240.1%
16.5%US$57.00US$30.00US$22.1114
Oct ’24n/a
US$43.53
0%
12.5%US$57.00US$35.00US$23.8015
Sep ’24US$18.43
US$44.00
+138.8%
12.7%US$57.00US$35.00US$14.8616
Aug ’24US$18.50
US$46.00
+148.7%
11.1%US$57.00US$36.00US$16.5516
Jul ’24US$23.52
US$46.13
+96.1%
10.8%US$57.00US$40.00US$13.0816
Jun ’24US$24.14
US$46.13
+91.1%
11.1%US$57.00US$40.00US$11.9015
May ’24US$27.94
US$46.79
+67.4%
10.2%US$57.00US$40.00US$13.7514
Apr ’24US$25.00
US$47.38
+89.5%
12.8%US$62.00US$40.00US$17.5313
Mar ’24US$33.17
US$46.92
+41.5%
14.6%US$62.00US$35.00US$19.9812
Feb ’24US$37.20
US$47.08
+26.6%
14.7%US$62.00US$35.00US$20.1512
Analyst Price Target
Consensus Narrative from 16 Analysts
US$41.54
Fair Value
59.8% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 06:07
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viridian Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Madhu KumarB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.